Kopfbereich

additional navigation

Logo

You are here:

AOP Newscenter


Press room

This section of our site provides general information about AOP Orphan. We will be happy to answer any questions or comments you may have:

T. +43 1 503 72 44-15
F. +43 1 503 72 44-5
publicaffairs(at)aoporphan.com

Dr Roland Bindeus (38) took control of the Hematology & Oncology Business Unit at the Austrian pioneer of rare diseases, AOP Orphan, at the beginning of April. The biochemist was most recently the general manager of Baxalta...

The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specialises in rare diseases, has appointed Suzie McFadzean to join the management team as Chief of Commercial Operations. British-born Suzie...

AOP Orphan Pharmaceuticals AG announced today the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member...

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

The Austrian pharmaceutical pioneer AOP Orphan is now bringing Lojuxta® (lomitapide) Capsules to the Austrian market

Today AOP Orphan Pharmaceuticals AG, Austria, and Rigi Healthcare AG, Switzerland, announced the creation of Rigi Orphan Inc, USA.  The new company will focus on the development, in-licensing and commercialization of...

INDIANAPOLIS, IN — CONFLUENCE PHARMACEUTICALS and AOP Orphan Pharmaceuticals AG (“AOP”), announced today they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the two special preparations by the highly innovative, publicly listed company Cardiome Pharma...

The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market. This means that the drug,...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.

In order to add impetus to the rapid expansion of recent years, the Austrian pharmaceutical company AOP Orphan is strengthening its management team.

AOP Orphan Pharmaceuticals has been awarded the exclusive distributions rights for Brinavess® (vernakalant) by Cardiome Pharma Corporation for most Central and Eastern European countries, as well as for Switzerland and Austria....

AOP Orphan Pharmaceuticals AG today announced the spin off of its 80 % stake in Activartis GmbH, a Vienna-based biotech company with a strong platform for immune-based cancer vaccines, to a group of private investors. The...

The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management experience to become CFO.

Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b...

A documentary on living with rare diseases; by Edith Bachkönig (currently available in German only)

At AOP Orphan are European pioneers in the field of Orphan Diseases. We research, develop, produce, and distribute innovative solutions for Rare Diseases worldwide.

With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian...


Contact

AOP Orphan Pharmaceuticals AG
Dr. Georg Fischer
Wilhelminenstraße 91/IIf
1160 Vienna
T. +43 1 503 72 44-15
F. +43 1 503 72 44-5
E-mail: publicaffairs(at)aoporphan.com

Products & Area of treatment